SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
BRISBANE, Calif., Nov. 29, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Dr. Tariq Arshad, acting Chief Medical Officer, will present on the potential for lenzilumab at the 2016 Juvenile Myelomonocytic Leukemia (JMML) International Symposium in San Diego, Calif., December 1-2, 2016.
KaloBios plans to assess interim data from its Phase 1 study of lenzilumab in chronic myelomonocytic leukemia (CMML), a rare hematologic cancer in older adults, to determine the feasibility of commencing a Phase 1 study in JMML, a rare pediatric form of CMML with high unmet medical need and no FDA-approved therapies. In July 2016, KaloBios initiated dosing in a Phase 1 clinical trial in patients with CMML to identify the maximum tolerated or recommended Phase 2 dose and to assess its safety, pharmacokinetics, and clinical activity. More information, including medical centers conducting the trial, can be found at https://clinicaltrials.gov/show/NCT02546284.
Details of the JMML International Symposium presentation follow:
Title: Potential Use of KB003/Lenzilumab in JMML
Presenter: Tariq Arshad, MD, MBA, KaloBios Pharmaceuticals
Date: Thursday, December 1, 2016
Time: 5:00 – 5:20 p.m. PST
Session: Update on Clinical Trials, Moderator: Charlotte Niemeyer, MD, University of Freiburg
For more information on the conference, please visit https://thejmmlfoundation.wildapricot.org/event-2150399.
About Lenzilumab
Lenzilumab is a Humaneered® recombinant monoclonal antibody that targets and is an antagonist of soluble Granulocyte Macrophage – Colony Stimulating Factor (GM-CSF), a cytokine suggested to be central to the inflammation and activation of certain immune cells. Lenzilumab has been studied for its ability to limit hypersensitivity to GM-CSF signaling, which appears to be a key feature in many CMML and JMML patients, and GM-CSF inhibition may affect the growth of leukemic cells in patients. Lenzilumab has been tested in more than 90 subjects in previous clinical trials in rheumatoid arthritis, asthma and healthy volunteers, and was found to be generally safe and well tolerated.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
